Protocol Ledger

NCT05646316 · Phase III · RECRUITING

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

Interventional Phase III clinical trial protocol NCT05646316 sponsored by NRG Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-07 Enrollment: 428 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05646316
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)428 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05646316
Protocol FieldVerified Registry Value
NCT IdentifierNCT05646316
Consolidated Lead SponsorNRG Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment428 participants (ESTIMATED)
Registered Start Date2022-12-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI